Depot Methylprednisolone

Phase 3Small molecule

MMassachusetts General Hospital

Depot Methylprednisolone is one of 2 small molecule programs targeting Adhesive Capsulitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adhesive CapsulitisRecruiting

Adhesive CapsulitisPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Adhesive Capsulitis

#DrugCompanyPhaseTrials

Depot Methylprednisolone

MMassachusetts General Hospital

Phase 3

1 2

Celestone

SSchering-Plough

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Adhesive Capsulitis

NCT02283996

Clinical

Trials by Indication[1]

Adhesive Capsulitis1 trial

Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

Recruiting·MMassachusetts General Hospital·Phase 4·NCT02283996·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Depot Methylprednisolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Depot Methylprednisolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Depot Methylprednisolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

Depot Methylprednisolone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Adhesive Capsulitis1 trial

References

Drug Info

Quick Facts

Related News